Search Results - "Créhange, G"

Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial – PROFIT by Zhou, K., Renouf, M., Perrocheau, G., Magné, N., Latorzeff, I., Pommier, P., Créhange, G., Paumier, A., Bera, G., Martin, J., Catton, C., Bellanger, M., Supiot, S.

“…•This is the first European cost-effectiveness analysis of moderately hypofractionated radiotherapy (H-RT) compared to conventional radiotherapy (C-RT).•Using…”
Get full text

Secondary neutron dose contribution from pencil beam scanning, scattered and spatially fractionated proton therapy by Leite, A M M, Ronga, M G, Giorgi, M, Ristic, Y, Perrot, Y, Trompier, F, Prezado, Y, Créhange, G, De Marzi, L

“…The Orsay Proton therapy Center (ICPO) has a long history of intracranial radiotherapy using both double scattering (DS) and pencil beam scanning (PBS)…”
Get more information

Moderately hypofractionated dose escalation radiotherapy for localized prostate cancer, ESHYPRO: Results of a retrospective single-centre series evaluating safety and efficacy by Quintin, K, Créhange, G, Graff, P

“…Prostate cancer is the most frequent cancer among men and radiotherapy hypofractionation regimens have become standard treatments for the localized stages, but…”
Get full text

Interest of positron-emission tomography and magnetic resonance imaging for radiotherapy planning and control by Créhange, G., Soussan, M., Gensanne, D., Decazes, P., Thariat, J., Thureau, S.

“…Computed tomography (CT) in the treatment position is currently indispensable for planning radiation therapy. Other imaging modalities, such as magnetic…”
Get full text

The radiosensitization effect of titanate nanotubes as a new tool in radiation therapy for glioblastoma: A proof-of-concept by Mirjolet, C, Papa, A.L, Créhange, G, Raguin, O, Seignez, C, Paul, C, Truc, G, Maingon, P, Millot, N

“…Abstract Background and purpose One of the new challenges to improve radiotherapy is to increase the ionizing effect by using nanoparticles. The interest of…”
Get full text

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study by Mirjolet, C., Charon-Barra, C., Ladoire, S., Arbez-Gindre, F., Bertaut, A., Ghiringhelli, F., Leroux, A., Peiffert, D., Borg, C., Bosset, J. F., Créhange, G.

“…Introduction: Some studies have suggested that baseline tumor-infiltrating-lymphocytes (TILs), such as CD8+ and FoxP3+ T-cells, may be associated with a better…”
Get full text

Breast radiation therapy during COVID-19 outbreak: Practical advice by Loap, P, Kirova, Y, Takanen, S, Créhange, G, Fourquet, A

Get full text

Which alpha/beta ratio for prostate cancer in 2019? by Cosset, J-M, Chargari, C, Créhange, G

“…In 1999, Brenner and Hall reported for prostate cancer a very low alpha/beta ratio (1.5Gy). In the following years, this value has been confirmed by a large…”
Get full text

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: Who, when, where and how? by Créhange, G., Roach, M., Martin, É., Cormier, L., Peiffert, D., Cochet, A., Chapet, O., Supiot, S., Cosset, J.-M., Bolla, M., Chung, H.T.

“…Even in the current era of dose-escalated radiotherapy for prostate cancer, biochemical recurrence is not uncommon. Furthermore, biochemical failure is not…”
Get full text

The role of radiation therapy for de novo metastatic bladder and renal cancers by Sargos, P., Le Guevelou, J., Khalifa, J., Albiges, L., Azria, D., de Crevoisier, R., Supiot, S., Créhange, G., Roubaud, G., Chapet, O., Pasquier, D., Blanchard, P., Latorzeff, I.

“…Metastatic bladder and renal cancers account respectively for 2.1% and 1.8% of cancer deaths worldwide. The advent of immune checkpoint inhibitors has…”
Get full text

External radiotherapy for prostatic cancers by de Crevoisier, R., Supiot, S., Créhange, G., Pommier, P., Latorzeff, I., Chapet, O., Pasquier, D., Blanchard, P., Schick, U., Marchesi, V., Sargos, P., Hennequin, C.

“…We present the update of the recommendations of the French society of oncological radiotherapy on external radiotherapy of prostate cancer. External…”
Get full text

Relationship between doses to anatomical structures and erectile dysfunction after radiotherapy for prostate cancer: A systematic review by Ailloud, A, Udrescu, C, Horn, S, Enachescu, C, Créhange, G, Sargos, P, Supiot, S, Zilli, T, Lapierre, A, Chapet, O

“…PURPOSEDuring prostatic radiotherapy, damage to several anatomical structures could be the cause of erectile dysfunction: corpora cavernosa, internal pudendal…”
Get full text

The role of proton therapy in esophageal cancer by Créhange, G, Goudjil, F, Krhili, S L, Minsat, M, de Marzi, L, Dendale, R

“…Because of the physical properties of proton beam radiation therapy (PT), which allows energy to be deposited at a specific depth with a rapid energy fall-off…”
Get full text

Understanding/acceptance of radiotherapy: An ethical dilemma resolved by an ethics of care by de Crevoisier, R, Leseur, J, Bouvet, C, Huguet, F, Lagrange, J-L, Haaser, T, Pasquier, D, Créhange, G, Supiot, S, Pommier, P, Roy, A, Berna, A, Blanchard, P, Marcucci, L

“…Ethical questions are poorly investigated specifically in radiation oncology. The objective of the study was to identify and understand the main ethical issue…”
Get full text

Limits of dose constraint definition for organs at risk specific to stereotactic radiotherapy by Beddok, A, Loi, M, Rivin Del Campo, E, Dumas, J-L, Orthuon, A, Créhange, G, Huguet, F

“…Stereotactic radiotherapy is a very hypofractionated radiotherapy (>7.5Gy per fraction), and therefore is more likely to induce late toxicities than…”
Get full text

Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series by Castelli, J., Feuvret, L., Haoming, Q. C., Biau, J., Jouglar, E., Berger, A., Truc, G., Gutierrez, F. Llamas, Morandi, X., Le Reste, P. J., Thillays, F., Loussouarn, D., Nouhaud, E., Crehange, G., Antoni, D., Vauleon, E., de Crevoisier, R., Noel, G.

“…The aims of this multicentre retrospective study were to identify prognostic or therapeutic factors impacting on overall survival in patients with gliosarcoma…”
Get full text

Radiotherapy of anal canal cancer by Peiffert, D., Huguet, F., Vendrely, V., Moureau-Zabotto, L., Rivin Del Campo, E., Créhange, G., Dietmann, A.-S., Moignier, A.

“…We present the update of the recommendations of the French society for radiation oncology on external radiotherapy and brachytherapy of anal canal carcinoma…”
Get full text

Impact of target volumes and radiation technique on loco-regional control and survival for patients with unilateral cervical lymph node metastases from an unknown primary by Ligey, A, Gentil, J, Créhange, G, Montbarbon, X, Pommier, P, Peignaux, K, Truc, G, Maingon, P

“…Abstract Purpose To compare the impact of an unilateral post-operative irradiation or a bilateral irradiation in terms of loco-regional control and survival in…”
Get full text

Indication and perspectives of radiation therapy in the setting of de-novo metastatic prostate cancer by Latorzeff, I., Camps-Maléa, A., Supiot, S., de Crevoisier, R., Farcy-Jacquet, M.-P., Hannoun-Lévi, J.-M., Riou, O., Pommier, P., Artignan, X., Chapet, O., Créhange, G., Marchesi, V., Pasquier, D., Sargos, P.

“…Prostate cancer is the most common cancer and the third leading cause of cancer mortality in men. Each year, approximately 10% of prostate cancers are…”
Get full text

Specificities of clinical research in radiotherapy by Hennequin, C., Azria, D., Blanchard, P., Créhange, G., Deutsch, É., Lisbona, A., Moyal, É., Pasquier, D., Roca, L., Supiot, S., Giraud, P.

“…The aim of this review is to present the specificities of clinical research in radiation oncology. Objectives are similar to all research in oncology: to…”
Get full text